Gilead Sciences, Inc. (GILD) Holdings Lifted by Pointe Capital Management LLC

Pointe Capital Management LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 149.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,135 shares of the biopharmaceutical company’s stock after buying an additional 6,080 shares during the quarter. Pointe Capital Management LLC’s holdings in Gilead Sciences were worth $717,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the business. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in shares of Gilead Sciences by 583.3% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares during the period. Penserra Capital Management LLC boosted its holdings in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the period. Webster Bank N. A. boosted its holdings in shares of Gilead Sciences by 51.7% during the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 624 shares during the period. American Beacon Advisors Inc. acquired a new stake in shares of Gilead Sciences during the first quarter worth approximately $143,000. Finally, Welch Group LLC boosted its holdings in shares of Gilead Sciences by 9.7% during the first quarter. Welch Group LLC now owns 2,857 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 252 shares during the period. Institutional investors own 73.98% of the company’s stock.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares in the company, valued at approximately $3,684,920. The disclosure for this sale can be found here. Insiders have sold a total of 486,819 shares of company stock worth $39,298,919 in the last quarter. Company insiders own 1.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://ledgergazette.com/2017/10/10/gilead-sciences-inc-gild-holdings-lifted-by-pointe-capital-management-llc.html.

Shares of Gilead Sciences, Inc. (GILD) opened at 81.98 on Tuesday. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27. The firm’s 50-day moving average is $81.25 and its 200-day moving average is $71.82. The firm has a market cap of $107.06 billion, a P/E ratio of 8.90 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same quarter last year, the business earned $3.08 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post $8.75 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Shareholders of record on Friday, September 15th were given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.54%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s payout ratio is 22.58%.

Several analysts recently commented on the stock. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Argus upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target for the company in a report on Thursday, August 31st. Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price target for the company. in a report on Monday, August 28th. Cowen and Company restated an “outperform” rating and set a $90.00 price target on shares of Gi

Several other institutional investors and hedge funds have also recently made changes to their positions in the business. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in shares of Gilead Sciences by 583.3% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares during the period. Penserra Capital Management LLC boosted its holdings in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the period. Webster Bank N. A. boosted its holdings in shares of Gilead Sciences by 51.7% during the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 624 shares during the period. American Beacon Advisors Inc. acquired a new stake in shares of Gilead Sciences during the first quarter worth approximately $143,000. Finally, Welch Group LLC boosted its holdings in shares of Gilead Sciences by 9.7% during the first quarter. Welch Group LLC now owns 2,857 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 252 shares during the period. Institutional investors own 73.98% of the company’s stock.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares in the company, valued at approximately $3,684,920. The disclosure for this sale can be found here. Insiders have sold a total of 486,819 shares of company stock worth $39,298,919 in the last quarter. Company insiders own 1.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://ledgergazette.com/2017/10/10/gilead-sciences-inc-gild-holdings-lifted-by-pointe-capital-management-llc.html.

Shares of Gilead Sciences, Inc. (GILD) opened at 81.98 on Tuesday. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27. The firm’s 50-day moving average is $81.25 and its 200-day moving average is $71.82. The firm has a market cap of $107.06 billion, a P/E ratio of 8.90 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same quarter last year, the business earned $3.08 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post $8.75 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Shareholders of record on Friday, September 15th were given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.54%. The ex-dividend date was Thursday, September 14th. Gilead Sciences’s payout ratio is 22.58%.

Several analysts recently commented on the stock. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Argus upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target for the company in a report on Thursday, August 31st. Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price target for the company. in a report on Monday, August 28th. Cowen and Company restated an “outperform” rating and set a $90.00 price target on shares of Gilead Sciences in a report on Wednesday, July 5th. Finally, Wells Fargo & Company raised their price target on shares of Gilead Sciences from $73.00 to $81.00 and gave the stock a “market perform” rating in a report on Wednesday, September 6th. Twelve equities research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $85.66.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply